Birkmayer W
Acta Neurol Scand Suppl. 1983;95:103-5. doi: 10.1111/j.1600-0404.1983.tb01522.x.
Deprenyl combined with levodopa and a peripheral decarboxylase inhibitor is of therapeutic value in the treatment of Parkinson's disease. This conclusion is substantiated by the improvement of akinesia, on-off phases, fluctuations of disability and rigidity. Levodopa doses can be reduced. The onset of adverse reactions is later and side-effects are even milder when compared to those with combined levodopa treatment. The most significant effect of deprenyl, however, is its ability to prolong the life expectancy of parkinsonian patients.
司来吉兰与左旋多巴及外周脱羧酶抑制剂联合使用在帕金森病治疗中具有治疗价值。运动不能、开关现象、残疾波动及强直症状的改善证实了这一结论。左旋多巴的剂量可以减少。与左旋多巴联合治疗相比，不良反应出现得更晚，副作用也更轻微。然而，司来吉兰最显著的作用是其能够延长帕金森病患者的预期寿命。
